Abstract:e24276 Background: Hepatocellular carcinoma (HCC), the most common hepatic malignancy, is the second leading cause of cancer-related death worldwide. China accounts for more than 50% of new HCC cases and deaths in the world. The genomic profiles of HCC in Chinese patients had not been thoroughly elucidated to facilitate diagnosis and treatment. Methods: FFPE tumor and matched blood samples of 181 Chinese HCC patients, including 152 males (median age of 54) and 29 females (median age of 52), were collected for next-generation sequencing-based 450 genes panel assay. Genomic alterations (including single base substitutions, short and long insertions/deletions, copy number variations, and gene rearrangement in selected genes) and tumor mutational burden were assessed. In addition, the expression of tumor cell PDL1 was also evaluated by FDA-cleared DAKO 22c3 antibody. Results: The most frequently mutated genes in 181 Chinese HCC were TP53 (59.7%), TERT (34.3%), CTNNB1 (21.5%), AXIN1 (12.2%), RB1 (11.0%), STK24 (11.0%), ARID1A (9.9%), CCND1 (7.7%), TSC2 (6.6%) and FGF19 (6.6%). The mutation rates of TERT (p = 0.027) and RB1 (p = 0.016) were significantly higher in patients (pts) with TMB greater than the cohort medium of 7.2 muts/Mb. In addition, loss of function mutation of PBRM1 was found in 2.8% of the pts. About 7% of the patients had TMB value higher than 20 muts/Mb, compared to 1-2% in Western HCC pts, and 31% higher than 10 muts/Mb. Seventy-four patients (median age 54 years; median TMB 6.8 muts/Mb) had tumorous PDL1 expressions assessed by IHC assay. Thirty-six percent of patients were positive of PDL1 (tumor portion score TPS greater than 1%). Only three pts possessed both high TMB and high PDL1 expression (TPS > 50). No correlation was observed between the expression of PDL1 and TMB (r = 0.1). Conclusions: This is the first genomic profiling study of Chinese HCC pts along with TMB and PDL1 expression results. With less actionable gene alterations but more often high TMB and PDL1 expression than their Western counterparts, Chinese HCC pts could potentially benefit more from immune check point inhibitor-based therapies. However, no correlation was observed between the expressions of PDL1 and TMB values.

The liver tissue bank and clinical database in China

Establishment and management of a liver tissue bank in China

Emerging Biomolecules for Practical Theranostics of Liver Hepatocellular Carcinoma.

Establishment, maintenance and management of liver tumor biobank

Liver Transplantation in Patients with Liver Failure: Twenty Years of Experience from China

The Establishment of Standardized Liver Cancer Tissue Bank

Establishment and Management of a Lung Cancer Biobank in Eastern China.

Characterization of Genomic Alterations, Tumor Mutational Burden and PDL1 Expression in 181 Chinese Hepatocellular Carcinomas.

LiverAtlas: a Unique Integrated Knowledge Database for Systems-Level Research of Liver and Hepatic Disease.

China Liver Transplant Registry Plays an Important Role in Liver Transplantation

Construction and Management of Breast Cancer Tissue Specimen Bank

Clinical Experience in Liver Transplantation from an Organ Transplantation Center in China.

Standardization construction of stem cell bank and information management system

Liver Transplantation in China: Problems and Their Solutions.

scLiverDB: a Database of Human and Mouse Liver Transcriptome Landscapes at Single‐Cell Resolution

Establishment of Tumor Database and Tissue Bank

Integrating Clinical and Biological Information in a Shanghai Biobank: an Introduction to the Sample Repository and Information Sharing Platform Project.

Establishment and maintenance of a standardized glioma tissue bank: Huashan experience

PDXliver: a Database of Liver Cancer Patient Derived Xenograft Mouse Models.

Liverbase: a comprehensive view of human liver biology.

Retrospect of 15-year construction and progress of biobank for gastrointestinal cancer in China